Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$79.00

0.229 (0.29%)

14:03
10/19/16
10/19
14:03
10/19/16
14:03

FDA grants accelerated approval to Eli Lilly's Lartruvo for soft tissue cancer

The U.S. FDA granted accelerated approval to Lartruvo, or olaratumab, with doxorubicin to treat adults with certain types of soft tissue sarcoma, which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline is an appropriate treatment. "This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin's approval more than 40 years ago," the agency noted. Lartruvo has "serious risks" including infusion-related reactions and embryo-fetal harm, the FDA added. Lartruvo is marketed by Eli Lilly.

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$79.00

0.229 (0.29%)

09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$249.02

1.67 (0.68%)

, TAL

TAL Education

$85.58

0.33 (0.39%)

13:51
02/27/17
02/27
13:51
02/27/17
13:51
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs, TAL Education »

Goldman Sachs reports…

GS

Goldman Sachs

$249.02

1.67 (0.68%)

TAL

TAL Education

$85.58

0.33 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 03

    Mar

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

, VCYT

Veracyte

$7.95

0.06 (0.76%)

13:50
02/27/17
02/27
13:50
02/27/17
13:50
Recommendations
Myriad Genetics, Veracyte analyst commentary  »

Piper sees CMS halt of…

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

VCYT

Veracyte

$7.95

0.06 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

13:50
02/27/17
02/27
13:50
02/27/17
13:50
General news
Treasury Action: yield have spiked higher as rate hike fears flare up »

Treasury Action: yield…

LJPC

La Jolla

$19.87

1.65 (9.06%)

13:39
02/27/17
02/27
13:39
02/27/17
13:39
Recommendations
La Jolla price target raised to $40 from $27 at Jefferies »

Jefferies analyst Eun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

NH

NantHealth

$7.54

-0.08 (-1.05%)

, MDRX

Allscripts

$12.05

-0.11 (-0.90%)

13:33
02/27/17
02/27
13:33
02/27/17
13:33
Hot Stocks
CTCA partners with Allscripts, NantHealth to launch Clinical Pathways »

Cancer Treatment Centers…

NH

NantHealth

$7.54

-0.08 (-1.05%)

MDRX

Allscripts

$12.05

-0.11 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

VRAY

ViewRay

$4.76

0.01 (0.21%)

13:30
02/27/17
02/27
13:30
02/27/17
13:30
Recommendations
ViewRay analyst commentary  »

ViewRay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 06

    Mar

AIG

AIG

$63.97

0.34 (0.53%)

13:29
02/27/17
02/27
13:29
02/27/17
13:29
Periodicals
AIG board to discuss whether to penalize or oust CEO over Q4 numbers, WSJ says »

AIG's directors are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

HAIN

Hain Celestial

$34.61

-0.23 (-0.66%)

13:26
02/27/17
02/27
13:26
02/27/17
13:26
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:19
02/27/17
02/27
13:19
02/27/17
13:19
Downgrade
bluebird bio rating change  »

Follow-up: bluebird bio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

$NSD

NASDAQ Market Internals

13:17
02/27/17
02/27
13:17
02/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
02/27/17
02/27
13:16
02/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:15
02/27/17
02/27
13:15
02/27/17
13:15
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

STM

STMicroelectronics

$15.49

0.485 (3.23%)

13:06
02/27/17
02/27
13:06
02/27/17
13:06
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$81.47

0.385 (0.47%)

13:05
02/27/17
02/27
13:05
02/27/17
13:05
Periodicals
Exxon CEO sees rising Permian production, continued Russia presence, Forbes says »

Speaking in a Forbes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

SAFM

Sanderson Farms

$94.44

-0.72 (-0.76%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Conference/Events
Sanderson Farms management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DDAIF

Daimler AG

$72.92

-0.39 (-0.53%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Hot Stocks
Daimler names Martin Daum head of Trucks, Buses divisions »

Daimler said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$186.67

-0.7399 (-0.39%)

13:00
02/27/17
02/27
13:00
02/27/17
13:00
Hot Stocks
IPTAB upholds validity of 3M Korean patent »

The Intellectual Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

trivago

$12.85

-0.13 (-1.00%)

12:57
02/27/17
02/27
12:57
02/27/17
12:57
Conference/Events
trivago management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

12:55
02/27/17
02/27
12:55
02/27/17
12:55
Hot Stocks
Samsung says new Facebook app available for Samsung TVs »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SNAP

Snap Inc.

12:52
02/27/17
02/27
12:52
02/27/17
12:52
Hot Stocks
Snap Inc: Some Class A shares subject to separate lock-up »

In an amended IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

MRVL

Marvell

12:51
02/27/17
02/27
12:51
02/27/17
12:51
Options
Notable premium seller in Marvell Tech »

Notable premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 10

    Mar

  • 04

    Apr

  • 05

    Apr

WLL

Whiting Petroleum

$10.95

0.15 (1.39%)

12:46
02/27/17
02/27
12:46
02/27/17
12:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

CLSD

Clearside Biomedical

$8.06

1.16 (16.81%)

12:45
02/27/17
02/27
12:45
02/27/17
12:45
Conference/Events
Clearside Biomedical has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SBGSY

Schneider Electric

$13.49

-0.21 (-1.53%)

12:44
02/27/17
02/27
12:44
02/27/17
12:44
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

  • 03

    Mar

MTB

M&T Bank

$168.14

-0.535 (-0.32%)

12:37
02/27/17
02/27
12:37
02/27/17
12:37
Hot Stocks
M&T Bank announces passing of COO Mark Czarnecki »

M&T Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.